| Elizabeth Tanzi, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-6776 | |
| Not Available |
| Full Name | Elizabeth Tanzi |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023178365 | NPI | - | NPPES |
| 407534000 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | D62179 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Tanzi, MD Po Box 64252, Baltimore, MD 21264-4252 Ph: () - | Elizabeth Tanzi, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-6776 |
News Archive
Women who suffer from migraines may take at least some comfort in a recent, first-of-its-kind study that suggests a history of such headaches is associated with a significantly lower risk of breast cancer. Christopher I. Li, M.D., Ph.D., and colleagues at Fred Hutchinson Cancer Research Center report these findings in the November issue of Cancer Epidemiology, Biomarkers and Prevention.
Many patients see their tumors shrink in response to a drug, only to have them come back with a vengeance as they evolve to fend off the treatment. Oncologists want to be able to quickly detect cancer drug resistance as it emerges in their patients and identify another drug the tumors will still respond to.
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.
› Verified 2 days ago
Sarah Nakib, MD, MPH Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Baltimore, MD 21287 Phone: 410-955-8662 | |
Crystal Ugochi Aguh, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1550 Orleans St, Crb Ii Room 211, Baltimore, MD 21287 Phone: 410-955-2400 Fax: 410-955-8645 | |
Dr. Larry H Gaston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2300 Garrison Blvd, Suite 260, Baltimore, MD 21216 Phone: 410-945-7544 Fax: 410-945-3605 | |
Dr. Manisha J. Loss, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Suite 8060b, Baltimore, MD 21287 Phone: 410-502-2082 | |
Dr. Marcia Sanford Driscoll, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 419 W Redwood St, Suite 160, Baltimore, MD 21201 Phone: 410-328-3167 Fax: 410-328-1323 | |
Dr. Myriam Lucia Vega Gonzalez, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St # 8072, Baltimore, MD 21287 Phone: 410-955-5933 Fax: 410-502-2309 |